A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intranasal Challenge With S. Pneumoniae

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intranasal Challenge With S. Pneumoniae

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs GEN 004 (Primary)
  • Indications Pneumococcal infections
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Genocea Biosciences
  • Most Recent Events

    • 09 Jun 2016 Data will be presented at the American Society for Microbiology annual general meeting (ASM Microbe 2016), according to a Genocea Biosciences media release.
    • 25 May 2016 Status changed from active, no longer recruiting to completed.
    • 05 Nov 2015 Planned End Date changed from 1 Mar 2016 to 1 May 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top